Toll Free: 1-888-928-9744
Published: Jul, 2015 | Pages:
27 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Sylentis S.A. - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'Sylentis S.A. - Product Pipeline Review - 2015', provides an overview of the Sylentis S.A.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Sylentis S.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Sylentis S.A. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Sylentis S.A.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Sylentis S.A.'s pipeline products Reasons to buy - Evaluate Sylentis S.A.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Sylentis S.A. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Sylentis S.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Sylentis S.A. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Sylentis S.A. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Explore the dormant and discontinued projects of Sylentis S.A. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Sylentis S.A. Snapshot 5 Sylentis S.A. Overview 5 Key Information 5 Key Facts 5 Sylentis S.A. - Research and Development Overview 6 Key Therapeutic Areas 6 Sylentis S.A. - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Sylentis S.A. - Pipeline Products Glance 10 Sylentis S.A. - Clinical Stage Pipeline Products 10 Phase II Products/Combination Treatment Modalities 10 Sylentis S.A. - Early Stage Pipeline Products 11 Preclinical Products/Combination Treatment Modalities 11 Discovery Products/Combination Treatment Modalities 12 Sylentis S.A. - Drug Profiles 13 bamosiran 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 SYL-1001 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 RNAi Oligonucleotide for Arthritis and Gastrointestinal Disorders 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 RNAi Oligonucleotide for Cerebral Ischemia and Dementia 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 Sylentis S.A. - Pipeline Analysis 18 Sylentis S.A. - Pipeline Products by Target 18 Sylentis S.A. - Pipeline Products by Route of Administration 19 Sylentis S.A. - Pipeline Products by Molecule Type 20 Sylentis S.A. - Pipeline Products by Mechanism of Action 21 Sylentis S.A. - Recent Pipeline Updates 22 Sylentis S.A. - Dormant Projects 24 Sylentis S.A. - Locations And Subsidiaries 25 Head Office 25 Appendix 26 Methodology 26 Coverage 26 Secondary Research 26 Primary Research 26 Expert Panel Validation 26 Contact Us 26 Disclaimer 27
List of Tables
Sylentis S.A., Key Information 5 Sylentis S.A., Key Facts 5 Sylentis S.A. - Pipeline by Indication, 2015 7 Sylentis S.A. - Pipeline by Stage of Development, 2015 8 Sylentis S.A. - Monotherapy Products in Pipeline, 2015 9 Sylentis S.A. - Phase II, 2015 10 Sylentis S.A. - Preclinical, 2015 11 Sylentis S.A. - Discovery, 2015 12 Sylentis S.A. - Pipeline by Target, 2015 18 Sylentis S.A. - Pipeline by Route of Administration, 2015 19 Sylentis S.A. - Pipeline by Molecule Type, 2015 20 Sylentis S.A. - Pipeline Products by Mechanism of Action, 2015 21 Sylentis S.A. - Recent Pipeline Updates, 2015 22 Sylentis S.A. - Dormant Developmental Projects,2015 24
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.